Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients

NCT01753167 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01753167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01753167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2012
Completion date
October 15, 2014
Enrollment
122 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infections